RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both "Clusters of excellence", Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects are dedicated to the development of new biological products based on the Lauriad™ technology allowing mucous penetration of a biologically active compound.

16 Dec 2010

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Repligen Corporation today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA"). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA.

15 Dec 2010

Anoles key to medically applicable regeneration?

Anolis lizards first entered Arizona State University biologist Kenro Kusumi's life in 1980 when, as a member of a junior curator program, he recorded in his field notebook that he had found an Anolis egg on a field trip. Kusumi still has those notes, along with other memorabilia that document the influence that both his early life and more recent experiences have had on his current pursuits in developmental biology.

15 Dec 2010

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

15 Dec 2010

Leeds scientists develop new vaccine to eliminate polio disease

Scientists at the University of Leeds are joining the global fight to eradicate polio by developing a new type of vaccine that can trick the body to develop immunity against the disease.

15 Dec 2010

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

15 Dec 2010

Hemispherx granted extension to modify Ampligen NDA for CFS indication

Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) granted a 12 month extension for the Company to modify its NDA in response to a Complete Response Letter (CRL) received November 25, 2009 for the CFS indication.

15 Dec 2010

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine and the University of Granada found that cFLIP -an inhibitor of death ligand-induced apoptosis- is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells.

14 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

14 Dec 2010

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved a revision to the dosing recommendation to include once-daily dosing of PREZISTA® (darunavir) tablets in combination with ritonavir for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients with no darunavir resistance-associated mutations (DRV RAMs).

13 Dec 2010

Stem cell biology offers great hope for eventual repair of body parts

Remarkable progress in understanding how stem cell biology works has been reported by a team of leading scientists, directed by experts at UC Santa Barbara. Their research has been published in the journal Cell Stem Cell.

13 Dec 2010

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Genomic Health, Inc. today announced the first results of a large prostate cancer study that identified 295 genes strongly associated with clinical recurrence following radical prostatectomy. Top-line findings from this study, which applied the same RT-PCR technology used in Genomic Health's Oncotype DX® breast and colon cancer tests, will be presented today at the Society for Urologic Oncology (SUO) annual meeting.

13 Dec 2010

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional dendritic cells (DC) from viremic patients.

13 Dec 2010

Haitian cholera pathogen closely related to 'El Tor O1' variant from South Asia

Scientists from Pacific Biosciences of California, Inc. and Harvard Medical School have successfully employed single molecule, real-time (SMRT™) DNA sequencing technology to rapidly characterize the pathogen responsible for the recent deadly cholera epidemic in Haiti. Published online Thursday in the New England Journal of Medicine, the results provide the first whole genome sequence analysis and most detailed genetic profile to date of the Haitian Vibrio cholerae outbreak strain.

10 Dec 2010

Silencing the TLR4 gene can prevent cardiovascular disease in diabetic patients

Silencing the TLR4 gene can stop the process which may lead to cardiovascular disease in diabetic patients. Researchers demonstrated that TLR4 plays a critical role in hyperglycaemic cardiac apoptosis, and that silencing the gene using specific small interfering RNA can prevent it.

10 Dec 2010

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Hemispherx Biopharma, Inc. announced that the Company has amended its June 15, 2010 agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com) to immediately include Mexico in the Territory under the Sales, Marketing, Distribution and Supply Agreement.

9 Dec 2010

RNA News and Research

Further Reading

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Genetic breakthrough in lung cancer

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Anoles key to medically applicable regeneration?

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Leeds scientists develop new vaccine to eliminate polio disease

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Hemispherx granted extension to modify Ampligen NDA for CFS indication

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Stem cell biology offers great hope for eventual repair of body parts

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Haitian cholera pathogen closely related to 'El Tor O1' variant from South Asia

Silencing the TLR4 gene can prevent cardiovascular disease in diabetic patients

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News